Ars Pharmaceuticals (SPRY) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
89.1M
Gross Profit
88.2M
98.90%
Operating Income
-3.1M
-3.46%
Net Income
8.0M
8.97%
Balance Sheet Metrics
Total Assets
351.2M
Total Liabilities
94.4M
Shareholders Equity
256.8M
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
3.3M
Free Cash Flow
13.0M
Revenue & Profitability Trend
Ars Pharmaceuticals Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 89.1M | 30.0K | 1.3M | 5.5M | 17.8M |
| Cost of Goods Sold | 977.0K | - | - | - | - |
| Gross Profit | 88.2M | - | - | - | - |
| Operating Expenses | 91.3M | 67.6M | 36.8M | 25.0M | 18.3M |
| Operating Income | -3.1M | -67.5M | -35.5M | -19.5M | -469.0K |
| Pre-tax Income | 8.3M | -54.4M | -34.7M | -20.2M | -1.1M |
| Income Tax | 288.0K | - | - | - | - |
| Net Income | 8.0M | -54.4M | -34.7M | -20.2M | -1.1M |
| EPS (Diluted) | - | -$0.57 | -$0.87 | -$0.22 | -$0.01 |
Income Statement Trend
Ars Pharmaceuticals Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 334.3M | 231.7M | 277.7M | 60.7M | 26.4M |
| Non-Current Assets | 16.9M | 1.5M | 3.7M | 716.0K | 25.0K |
| Total Assets | 351.2M | 233.2M | 281.4M | 61.4M | 26.4M |
| Liabilities | |||||
| Current Liabilities | 23.4M | 2.4M | 5.4M | 8.2M | 8.2M |
| Non-Current Liabilities | 70.9M | 37.0K | 3.1M | 84.5M | 32.2M |
| Total Liabilities | 94.4M | 2.4M | 8.5M | 92.7M | 40.5M |
| Equity | |||||
| Total Shareholders Equity | 256.8M | 230.8M | 272.9M | -31.3M | -14.1M |
Balance Sheet Composition
Ars Pharmaceuticals Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 8.0M | -54.4M | -34.7M | -20.2M | -1.1M |
| Operating Cash Flow | 3.3M | -55.1M | -28.7M | -19.5M | 9.6M |
| Investing Activities | |||||
| Capital Expenditures | -563.0K | -175.0K | -199.0K | -55.0K | 0 |
| Investing Cash Flow | -106.1M | -87.2M | -199.0K | -55.0K | 0 |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 69.4M | 0 | 190.2M | 53.0M | 5.0M |
| Free Cash Flow | 13.0M | -59.4M | -40.3M | -17.6M | 9.1M |
Cash Flow Trend
Ars Pharmaceuticals Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
168.25
Forward P/E
-22.08
Price to Book
7.19
Price to Sales
16.97
PEG Ratio
-22.08
Profitability Ratios
Profit Margin
-16.11%
Operating Margin
-466.29%
Return on Equity
-6.91%
Return on Assets
-6.10%
Financial Health
Current Ratio
11.00
Debt to Equity
30.33
Beta
0.87
Per Share Data
EPS (TTM)
-$0.16
Book Value per Share
$2.33
Revenue per Share
$1.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| spry | 1.6B | 168.25 | 7.19 | -6.91% | -16.11% | 30.33 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.